Healthcare shares are generally mixed in pre-market trade.
Among news in this sector, Ariad Pharmaceuticals (
) is up more than about 3% pre-market, easing off stronger gains,
gaining for a fourth session, amid speculation it may be a takeover
target for a larger drug maker. ARIA closed up 19% Friday.
And, BioCryst Pharmaceuticals, Inc. (
) is down about 10% pre-market after it was downgraded by Wells
Fargo to a Market Perform rating from Outperform. The firm set the
stock's price range at $9-$10 a share.
Finally, blood management solutions provider Haemonetics
) is down 3% after it said its adjusted EPS for Q3 2014 was up 5%
year-over-year to $0.61, a penny better than the Capital IQ
Net revenues were down 2% from last year to $242.1 million,
versus the $244 million analyst estimate.
For fiscal 2014, the company continues to expect adjusted EPS of
$2.30 to $2.40, which compares to the $2.32 street view. Overall
fiscal 2014 organic revenue is still expected to grow 2%-4% in
constant currency and 0%-2% on a reported basis.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.